Merck Pitches HIV Pipeline as $5B Diversifier, but Near-Term Checkpoints Still Dominate

What happened

Merck presented Phase III data for a once-weekly oral HIV treatment and plans for a monthly oral PrEP candidate, targeting a combined $5 billion growth opportunity as it works to reduce dependence on Keytruda. The event comes against the backdrop of a concentrated portfolio where Keytruda accounts for 49% of 2025 sales and faces a two-step decline from biosimilars and IRA pricing starting 2028. While the HIV pipeline adds to Merck's series of business development moves and restructuring savings aimed at building post-Keytruda revenue pillars, the commercial impact remains years away and faces intense competition from entrenched players like Gilead. The near-term investment thesis remains anchored to containing the $2.5 billion 2026 headwind from generics and price setting, and to seeing a resumption of Gardasil shipments to China. For now, the HIV news provides incremental evidence of pipeline progress but does not alter the critical 6-12 month checkpoints of China recovery and erosion containment.

Implication

While a $5B aspirational HIV franchise would help reduce Keytruda concentration, the timeline to meaningful revenue is distant, and the market remains focused on the immediate $2.5B 2026 headwind and the unresolved Gardasil China shipment pause. The HIV data is promising but commercially unproven, and Merck faces entrenched competition in HIV from Gilead and ViiV, making rapid market-share gains unlikely. Until Gardasil normalizes and the Keytruda cliff is better quantified, these pipeline assets are insufficient to upgrade our WAIT rating. We see no reason to deviate from our $125 base case, as the investment case still requires observable catalysts like China shipment resumption and a stable erosion bridge. The event may modestly support sentiment, but it does not change the mandatory re-assessment window of 6-12 months.

Thesis delta

The HIV pipeline event introduces a potential long-term growth driver that could aid post-Keytruda diversification, but its commercial impact is too distant to shift our current WAIT thesis. Our base case remains anchored to Keytruda stability through 2026 and Gardasil China recovery; the HIV assets do not address the near-term headwinds. Confidence in the pipeline may improve modestly, but we await concrete proof of execution and timeline clarity.